Literature DB >> 25457026

Intermediate-length polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese patients with amyotrophic lateral sclerosis.

Hai-Peng Lu1, Shi-Rui Gan2, Sheng Chen2, Hong-Fu Li3, Zhi-Jun Liu4, Wang Ni5, Ning Wang2, Zhi-Ying Wu6.   

Abstract

An effective treatment for amyotrophic lateral sclerosis (ALS) has not yet been found because the pathogenesis of this fatal disease is not well understood. A number of previous studies demonstrated that intermediate-length polyglutamine repeats within the ataxin-2 gene (ATXN2) might be a risk factor among patients with ALS in Western countries. Here, we aim to determine whether this sequence is a risk factor in Eastern Chinese ALS patients. Therefore, 379 unrelated sporadic ALS patients, 15 unrelated familial ALS patients, and 900 neurologically normal controls were studied. The ATXN2 CAG repeats were amplified using polymerase chain reaction. The products were separated on an 8% polyacrylamide gel and confirmed using Sanger sequencing. The results were evaluated using SPSS 17.0. We found that ATXN2 intermediate-length polyglutamine expansions greater than 24 and 27 repeats were associated with sporadic ALS. Our finding supports the hypothesis that ATXN2 plays an important role in the pathogenesis of ALS.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATXN2; Amyotrophic lateral sclerosis; Association; Chinese

Mesh:

Substances:

Year:  2014        PMID: 25457026     DOI: 10.1016/j.neurobiolaging.2014.10.015

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  7 in total

1.  Association of ATXN2 intermediate-length CAG repeats with amyotrophic lateral sclerosis correlates with the distributions of normal CAG repeat alleles among individual ethnic populations.

Authors:  Hiroya Naruse; Takashi Matsukawa; Hiroyuki Ishiura; Jun Mitsui; Yuji Takahashi; Hiroki Takano; Jun Goto; Tatsushi Toda; Shoji Tsuji
Journal:  Neurogenetics       Date:  2019-03-07       Impact factor: 2.660

Review 2.  RNA-binding proteins with prion-like domains in health and disease.

Authors:  Alice Ford Harrison; James Shorter
Journal:  Biochem J       Date:  2017-04-07       Impact factor: 3.857

3.  The Clinical and Polynucleotide Repeat Expansion Analysis of ATXN2, NOP56, AR and C9orf72 in Patients With ALS From Mainland China.

Authors:  Xiaorong Hou; Wanzhen Li; Pan Liu; Zhen Liu; Yanchun Yuan; Jie Ni; Lu Shen; Beisha Tang; Junling Wang
Journal:  Front Neurol       Date:  2022-05-06       Impact factor: 4.086

Review 4.  The epidemiology and genetics of Amyotrophic lateral sclerosis in China.

Authors:  Xiaolu Liu; Ji He; Fen-Biao Gao; Aaron D Gitler; Dongsheng Fan
Journal:  Brain Res       Date:  2018-03-01       Impact factor: 3.610

Review 5.  RNA-Binding Proteins in Amyotrophic Lateral Sclerosis.

Authors:  Melody Zhao; Jihye Rachel Kim; Rebekah van Bruggen; Jeehye Park
Journal:  Mol Cells       Date:  2018-08-29       Impact factor: 5.034

Review 6.  Genotype-phenotype correlations of amyotrophic lateral sclerosis.

Authors:  Hong-Fu Li; Zhi-Ying Wu
Journal:  Transl Neurodegener       Date:  2016-02-03       Impact factor: 8.014

7.  ATXN2 trinucleotide repeat length correlates with risk of ALS.

Authors:  William Sproviero; Aleksey Shatunov; Daniel Stahl; Maryam Shoai; Wouter van Rheenen; Ashley R Jones; Safa Al-Sarraj; Peter M Andersen; Nancy M Bonini; Francesca L Conforti; Philip Van Damme; Hussein Daoud; Maria Del Mar Amador; Isabella Fogh; Monica Forzan; Ben Gaastra; Cinzia Gellera; Aaron D Gitler; John Hardy; Pietro Fratta; Vincenzo La Bella; Isabelle Le Ber; Tim Van Langenhove; Serena Lattante; Yi-Chung Lee; Andrea Malaspina; Vincent Meininger; Stéphanie Millecamps; Richard Orrell; Rosa Rademakers; Wim Robberecht; Guy Rouleau; Owen A Ross; Francois Salachas; Katie Sidle; Bradley N Smith; Bing-Wen Soong; Gianni Sorarù; Giovanni Stevanin; Edor Kabashi; Claire Troakes; Christine van Broeckhoven; Jan H Veldink; Leonard H van den Berg; Christopher E Shaw; John F Powell; Ammar Al-Chalabi
Journal:  Neurobiol Aging       Date:  2016-11-24       Impact factor: 5.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.